Nanexa and Novo enter into EUR 1.165 billion global license and collaboration agreement for long-acting injectables

PartnershipPharmaShell®Positive

AI Analysis

Summary

Nanexa and Novo entered into a EUR 1.165 billion global exclusive license and collaboration agreement for Nanexa's PharmaShell® ALD drug delivery technology platform for therapeutic peptides in obesity, type 2 diabetes, and cardiometabolic indications.

Outcome Details

Global exclusive license agreement for long-acting injectables platform

Importance:7/10

Sentiment:

0.70

LicensingCollaborationDrug Delivery TechnologyPeptide DrugsCardiometabolicLong-Acting Injectables

Related Companies

$GBCMD $DMIIR

Read the original article

Published by PR Newswire Pharma on September 25, 2026 12:00 PM

Read Original